U.S. market Closed. Opens in 22 hours 8 minutes

TCRT | Alaunos Therapeutics, Inc. Stock Overview

(Stock Exchange: NASDAQ)
Day's Range 1.4600 - 1.6000
52 Week Range 1.4200 - 18.90
Beta 0.05
Implied Volatility 286.16%
IV Rank 54.90%
Day's Volume 3,337
Average Volume 14,258
Shares Outstanding 1,601,250
Market Cap 2,337,825
Sector Healthcare
Industry Biotechnology
IPO Date 2005-08-24
Valuation
Profitability
Growth
Health
P/E Ratio N/A
Forward P/E Ratio N/A
EPS -315.39
1YR Price Target N/A
Dividend Yield N/A
Dividend Per Share N/A
Dividend ExDate N/A
Dividend PayDate N/A
Employees 1
Country USA
Website TCRT
Alaunos Therapeutics Inc is a clinical-stage cellular immuno-oncology company dedicated to the treatment of solid tumors through adoptive TCR-T cell therapy. It strikes cancer at its core by engineering cell therapies that target Neoantigens (neoAg) arising from genomic mutations.
TCRT's peers: RIGL, INKT, PIRS, MRSN, VRCA, FENC, LRMR, LIAN, ADAP, STOK, FIXX, BDTX, HARP, ACHL, CKPT, CUE, MDNA
*Chart delayed
Analyzing fundamentals for TCRT we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is bad and Health is frighteningly weak. For more detailed analysis please see TCRT Fundamentals page.

Watching at TCRT technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on TCRT Technicals page.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙